Trifluridine-tipiracil

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, The Methodist Hospital Research Institute

Conditions

Advanced Solid TumorsGastroesophageal CancerMetastatic Colorectal Cancer (CRC)

Phase 1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

RecruitingNCT04626635

Regeneron PharmaceuticalsAdvanced Solid Tumors

Start: 2020-12-21End: 2027-04-07Target: 933Updated: 2026-02-02

Phase 2

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

RecruitingNCT06887218

The Methodist Hospital Research InstituteMetastatic Colorectal Cancer (CRC)

Start: 2025-05-08End: 2029-12-31Target: 57Updated: 2025-08-27

Phase 3

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Active, not recruitingNCT06356311

Merck Sharp & Dohme LLCGastroesophageal Cancer

Start: 2024-05-03End: 2027-05-06Target: 450Updated: 2026-02-27

Related Papers

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.

Journal of Clinical Oncology2024-06-017 citations

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Journal of Clinical Oncology2024-01-20

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Journal of Clinical Oncology2023-01-245 citations

735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results

Regular and Young Investigator Award Abstracts2022-11-013 citations

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-014 citations